Dravet Syndrome
📧 Sign up to get email alerts when something new happens for Dravet Syndrome.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-10-20FDA Approved: EPIDIOLEX — Supplemental Application (Jazz Pharmaceuticals, Inc.)
FDA approved a supplemental application for Epidiolex (cannabidiol) submitted by Jazz Pharmaceuticals, Inc. The action updates the labeling …
-
CLINICAL_TRIALS trial_result · 2023-09-25Clinical Trial Update: An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome [Phase 3]
An open-label extension Phase 3 trial assessing the long-term safety of ZX008 (fenfluramine hydrochloride) oral solution in children and you…
-
FDA approval · 2023-09-14FDA Approved: FINTEPLA — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for FINTEPLA (fenfluramine) from UCB, Inc.; the approval updates the drug's labeling and/or indicati…
-
FDA approval · 2023-05-30FDA Approved: FINTEPLA — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for FINTEPLA (fenfluramine) from UCB, Inc., indicating an approved update to its labeling/indication…
-
CLINICAL_TRIALS trial_result · 2023-02-16Clinical Trial Update: Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome [Phase 2]
Phase 2 trial update for ataluren in nonsense mutation-related CDKL5 and Dravet syndrome (epilepsy) has completed with results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-11-09Clinical Trial Update: Fenfluramine for Adult Dravet Patients [Phase 3]
Trial update for fenfluramine in adult Dravet patients is in Phase 3 with unclear status.
-
CLINICAL_TRIALS trial_result · 2022-10-19Clinical Trial Update: A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome [Phase 3]
Phase 3 trial evaluating ZX008 (fenfluramine hydrochloride) oral solution as adjunctive therapy in children 2 years and older with Dravet sy…
-
CLINICAL_TRIALS trial_result · 2022-10-19Clinical Trial Update: A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome [Phase 3]
Phase 3 trial of two fixed doses of fenfluramine (ZX008) in children and young adults with Dravet syndrome has completed with results posted…
-
FDA approval · 2022-06-15FDA Approved: FINTEPLA — Supplemental Application (UCB, Inc.)
The FDA lists a supplemental application for Fintepla (fenfluramine) from UCB, Inc., indicating potential changes to labeling or indications…
-
FDA approval · 2022-03-25FDA Approved: FINTEPLA — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for Fintepla (fenfluramine) submitted by UCB, Inc.
-
CLINICAL_TRIALS trial_result · 2022-02-03Clinical Trial Update: An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes [Phase 3]
Open-label extension study of cannabidiol (GWP42003-P) in children and adults with Dravet or Lennox-Gastaut syndromes completed; results pos…
-
CLINICAL_TRIALS trial_result · 2022-01-03Clinical Trial Update: The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy [Phase 1, Phase 2]
A terminated phase 1/2 clinical trial evaluating the effects of cannabidiol (CBD) on electrical and autonomic cardiac function in children w…
-
FDA approval · 2021-09-30FDA Approved: EPIDIOLEX — Supplemental Application (Jazz Pharmaceuticals, Inc.)
The FDA has approved a supplemental application for Epidiolex (cannabidiol) from Jazz Pharmaceuticals, Inc., indicating an update to its app…
-
CLINICAL_TRIALS trial_result · 2021-03-23Clinical Trial Update: Verapamil as Therapy for Children and Young Adults With Dravet Syndrome [Phase 2]
Phase 2 trial investigating verapamil as therapy for children and young adults with Dravet syndrome has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-02-18Clinical Trial Update: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies [Phase 2]
Phase 2 trial in pediatric epilepsy evaluating TAK-935 as adjunctive therapy; completed with posted results.
-
CLINICAL_TRIALS trial_result · 2020-11-02Clinical Trial Update: Research on Cognitive Effect of Cannabidiol on Dravet Syndrome and Lennox-Gastaut SyndromeGastaut Syndrome [Phase 3]
Phase 3 trial update investigating the cognitive effects of cannabidiol in Dravet Syndrome and Lennox-Gastaut Syndrome.
-
FDA approval · 2020-10-22FDA Approved: EPIDIOLEX — Supplemental Application (Jazz Pharmaceuticals, Inc.)
FDA approved a supplemental application for Epidiolex (cannabidiol) from Jazz Pharmaceuticals.
-
FDA approval · 2020-07-31FDA Approved: EPIDIOLEX — Supplemental Application (Jazz Pharmaceuticals, Inc.)
FDA approves a supplemental application for Epidiolex (cannabidiol) from Jazz Pharmaceuticals, expanding its labeling to reflect additional …
-
FDA approval · 2020-06-25FDA Approved: FINTEPLA — Original Application (UCB, Inc.)
FDA approved the original application for Fintepla (fenfluramine) by UCB, Inc., to treat convulsive seizures associated with Dravet syndrome…
-
CLINICAL_TRIALS trial_result · 2019-08-01Clinical Trial Update: GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome [Phase 3]
A Phase 3 trial evaluating cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome has completed with results posted in 2…
-
FDA approval · 2019-05-22FDA Approved: EPIDIOLEX — Supplemental Application (Jazz Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Epidiolex (cannabidiol) from Jazz Pharmaceuticals, updating the labeling to reflect the new …
-
FDA approval · 2018-12-12FDA Approved: EPIDIOLEX — Supplemental Application (Jazz Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Epidiolex (cannabidiol) submitted by Jazz Pharmaceuticals, Inc. The action updates the produ…
-
CLINICAL_TRIALS trial_result · 2018-07-20Clinical Trial Update: Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1) [Phase 3]
Phase 3 trial update on GWP42003-P in children and young adults with Dravet syndrome. Completed with results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-07-19Clinical Trial Update: A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1) [Phase 2]
Phase 2 dose-ranging pharmacokinetics and safety study of GWP42003-P in children with Dravet syndrome completed; results posted in 2018.
-
FDA approval · 2018-06-25FDA Approved: EPIDIOLEX — Original Application (Jazz Pharmaceuticals, Inc.)
FDA approved Epidiolex (cannabidiol) under its original application for treating seizures in Lennox-Gastaut syndrome and Dravet syndrome. Th…